After the rejection of Lykos Therapeutics’ MDMA-based PTSD treatment tempered excitement for psychedelic therapeutics, a ...
They also note that the oral tablets would be less prone to abuse and diversion than other ketamine formulations. They could also be cheaper, given that Spravato's US list price in the US is $590 ...
Spravato is the first ketamine-based medicine approved to treat depression, and also the first of a new class of glutamate NMDA receptor-targeting drugs that have ended a decades-long drought at ...
The largest life sciences association in the state recognized those driving discovery during its 32nd annual dinner meeting ...
Living Local 15 host Jessica Williams is joined by Sean Goddard, a Psychiatric Nurse Practitioner and Owner of Viking Psychiatry, to speak about the recent approval for Spravato as a monotherapy ...